Fosun Pharma’s Serplulimab Approved for Esophageal Squamous Cell Carcinoma and Grafalon for GvHD Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has issued updates on the development statuses...
Clinical trial approval / initiation
Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Solid Tumor Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that it...
Hybio Pharmaceutical Gets NMPA Approval for COVID-19 Nasal Spray HY3000
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has received approval from the National Medical Products...
Jiangsu Hengrui Pharmaceuticals Wins NMPA Approval for Two Novel Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced receiving...
Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors
Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to...
Walvax Biotechnology Receives Indonesian FDA Approval for Phase III Pneumococcal Vaccine Trial
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received approval from...
Sunshine Guojian Pharmaceutical Gets NMPA Approval for SSGJ-611 Phase II COPD Study
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...
Zhejiang Medicine Gets NMPA Approval for NCB003 Clinical Study for Advanced Solid Tumors
Zhejiang Medicine Co., Ltd (SHA: 600216), a China-based pharmaceutical company, has announced that it has...
Akeso Biopharma’s AK132 Receives Green Light for Clinical Trial in Advanced Solid Tumors
Akeso Biopharma’s (HKG: 9926) AK132, a bispecific antibody (BsAb) targeting Claudin18.2 and CD47, has received...
Chongqing Lummy Pharmaceutical’s Subsidiary Receives NMPA Approval for CUD002 mRNA Vaccine
Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006), through its subsidiary Sichuan Cunde Therapeutics Co., Ltd,...
InnoCare Pharma and ArriVent Biopharma Partner on Clinical Study for Advanced NSCLC Treatment
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced that it has received the green...
Boehringer Ingelheim Gets NMPA Approval for Brigimadlin Safety and Efficacy Study in China
Germany-based Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical...
Gan & Lee Pharmaceuticals Initiates Phase II Clinical Study for Weekly Insulin GZR4
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the dosing of...
HutchMed Advances Tazverik Phase II Trial for Follicular Lymphoma in China
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in a...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for HRS-7450 Acute Ischemic Stroke Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
SinoMab BioScience Receives NMPA Approval for Phase I Study of Atopic Dermatitis Drug SM17
Hong Kong-based biotechnology company SinoMab BioScience Ltd (HKG: 3681) has received approval from the National...
Haisco Pharmaceutical Gets NMPA Approval for HSK21542 Chronic Pruritus Clinical Study
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received approval...
United Laboratories’ UBT251 Receives Tacit Approval for NAFLD Clinical Study in China
Hong Kong firm United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category...
Abbisko Therapeutics Receives EMA Approval for Phase III Study of Pimicotinib for TGCT
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...
AriBio Files for Phase III Clinical Trial Approval in China for Alzheimer’s Drug AR1001
South Korean clinical-stage biotech AriBio Co. has announced the filing for Phase III clinical trial...